Melanin-Concentrating Hormone Receptor-1 Antagonists as Antiobesity Therapeutics: Current Status

Kowalski, Timothy J.; Sasikumar, Thavalakulamgar
September 2007
BioDrugs;2007, Vol. 21 Issue 5, p311
Academic Journal
There is compelling genetic and pharmacologic evidence to indicate that melanin-concentrating hormone receptor-1 (MCHR1) signaling is involved in the regulation of food intake and energy expenditure. The medical need for novel therapies to treat obesity and related metabolic disorders has led to a great deal of interest by pharmaceutical companies in the discovery of MCHR1 antagonists. Recent publications describing preclinical studies have demonstrated that small-molecule MCHR1 antagonists decrease food intake, bodyweight, and adiposity in rodent models of obesity. Results from ongoing early-stage clinical trials with MCHR1 antagonists are eagerly awaited, as is the movement of other MCHR1 antagonists into the clinic.


Related Articles

  • Lead Optimization Strategies and Tactics Applied to the Discovery of Melanin Concentrating Hormone Receptor 1 Antagonists. Kym, Philip R.; Judd, Andrew S.; Lynch, John K.; Iyengar, Rajesh; Vasudevan, Anil; Souers, Andrew J. // Current Topics in Medicinal Chemistry;Aug2007, Vol. 7 Issue 15, p1471 

    The discovery of small molecule melanin concentrating hormone receptor (MCHr1) antagonists as novel therapeutic agents for the treatment of obesity has been actively pursued across the pharmaceutical industry. While multiple chemotypes of small molecule MCHr1 antagonists have been identified and...

  • PGC-1a: A Multifunctional Transcriptional Coactivator Involved in Human Metabolic Disorders. Oberkofler, H.; Krempler, F.; Patsch, W. // Current Genomics;Jul2004, Vol. 5 Issue 5, p443 

    Nuclear hormone receptor function is controlled by a number of ancillary factors termed coregulators. Such coactivators and corepressors afford considerable flexibility in the coordinate expression of gene networks in numerous physiological, developmental and metabolic processes. PGC-1a,...

  • Functions of neuronal adenosine receptors. Haas, Helmut L.; Selbach, Oliver // Naunyn-Schmiedeberg's Archives of Pharmacology;Nov2000, Vol. 362 Issue 4/5, p375 

    Endogenous adenosine in nervous tissue, a central link between energy metabolism and neuronal activity, varies according to behavioral state and (patho)physiological conditions; it may be the major sleep propensity substance. The functional consequences of activation of the four known adenosine...

  • Allele-Specific, Age-Dependent and BMI-Associated DNA Methylation of Human MCHR1. Stepanow, Stefanie; Reichwald, Kathrin; Huse, Klaus; Gausmann, Ulrike; Nebel, Almut; Rosenstiel, Philip; Wabitsch, Martin; Fischer-Posovszky, Pamela; Platzer, Matthias // PLoS ONE;2011, Vol. 6 Issue 5, p1 

    Background: Melanin-concentrating hormone receptor 1 (MCHR1) plays a significant role in regulation of energy balance, food intake, physical activity and body weight in humans and rodents. Several association studies for human obesity showed contrary results concerning the SNPs rs133072 (G/A)...

  • How many sites of action for endocannabinoids to control energy metabolism? Pagotto, U; Cervino, C; Vicennati, V; Marsicano, G; Lutz, B; Pasquali, R // International Journal of Obesity;Apr2006 Supplement 1, Vol. 30, pS39 

    The promising results obtained by clinical trials using Rimonabant to tackle visceral obesity and related disorders recently promoted a remarkable impulse to carry out detailed investigations into the mechanisms of action of endocannabinoids in regulating food intake and energy metabolism. The...

  • Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs. Dozio, E.; Ruscica, M.; Motta, M.; Magni, P. // Mini Reviews in Medicinal Chemistry;Jan2007, Vol. 7 Issue 1, p11 

    Food intake and energy homeostasis are controlled by peripheral humoral signals, afferent neuronal pathways to the brain and central signals, represented, in particular, by neuropeptides. This review reports the status of development of novel compounds targeting some hypothalamic neuropeptide...

  • New Targets for Obesity Pharmacotherapy. Aronne, L. J.; Thornton-Jones, Z. D. // Clinical Pharmacology & Therapeutics;May2007, Vol. 81 Issue 5, p748 

    An understanding of the mechanisms that regulate energy homeostasis is essential for understanding novel obesity therapies. The status of energy reserves is communicated to the brain by adiposity and satiety signals. These signals modify either anabolic or catabolic pathways and, consequently,...

  • Capítulo1: Metabolismo energético. Krupa Das, Sai; B. Roberts, Susan // Conocimientos Actuales sobre Nutrición;2003, p3 

    The energetic equilibrium is adjusted by particularly sensitive mechanisms which have been identified during the present investigations. The disorders in the energetic equilibrium emerge from the genetic and environmental causes and explain many of the current common health problems in the...

  • Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications.  // American Journal of Clinical Nutrition;Jan2009, Vol. 89 Issue 1, p45 

    The article discusses the impact of novel capsinoid treatment on the energy metabolism and fatness in humans. An overview on the safety and efficacy of oral capsinoids for fat and weight loss, is provided. Also emphasized is the capsinoid response of genes as well as the measurement of body mass...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics